Promising combo tackles Hard-to-Treat breast cancer

NCT ID NCT02705859

Completed Disease control Sponsor: Cancer Trials Ireland Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-phase trial tested a combination of two drugs—copanlisib and trastuzumab—in 26 women with advanced HER2-positive breast cancer that had worsened after prior treatment. The goal was to find the safest dose and see if the combination could shrink tumors or slow disease progression. Results will help decide if larger studies are warranted.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Copanlisib (a targeted cancer drug) combined with trastuzumab (Herceptin)
What this could lead to: If successful, this combination could offer a new treatment option for patients with HER2-positive breast cancer that has stopped responding to standard therapies.
What could go wrong: This is an early-phase trial with only 26 participants, so results may not apply broadly. The drug combination may cause side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HER2-POSITIVE BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HER2 positive breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HER2-POSITIVE BREAST CANCER

Contacts and locations

Locations

Cancer Trials Ireland Investigative Site

Cork, Ireland
Cancer Trials Ireland Investigative Site

Dublin, Ireland
Cancer Trials Ireland Investigative Site

Galway, Ireland

More trials for these conditions

Other studies related to the condition(s) this trial covers.